Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment

Clinical Infectious Diseases

Volumn 48, Issue 6, 2009, Pages 787-794

  Kelley, Colleen F ^a   Kitchen, Christina M R ^b   Hunt, Peter W ^c   Rodriguez, Benigno ^d   Hecht, Frederick M ^c   Kitahata, Mari ^e   Crane, Heide M ^e   Willig, James ^f   Mugavero, Michael ^f   Saag, Michael ^f   Martin, Jeffrey N ^c   Deeks, Steven G ^c,g  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT DURATION; VIRUS LOAD; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 62449222132     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597093     Document Type: Article

References (34)

1. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6:280-7.
2. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
3. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-8.
4. + T-cell count. J Acquir Immune Defic Syndr 2004;36:702-13.
5. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6.
6. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003;163:2187-95.
7. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy. I Acquir Immune Defic Syndr 2001;27:168-75.
8. 3 or greater. J Acquir Immune Defic Syndr 2007;45:183-92.
9. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003;17:1907-15.
10. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007;370:407-13.
11. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, 1 December 2007:1-143. Available at: http://www.aidsinto.nih.gov/ContentFiles/AdultandAdolescentGL.pdf'. Accessed 16 December 2007.
12. Le Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med 2007;8:156-63.
13. + count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008;22:841-8.
14. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
15. Weber R, Sab in CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41.
16. Gutierrez F, Padilla S, Masia M, et al. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 2006;1:e89.
17. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006;20:371-7.
18. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7.
19. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-72.
20. + cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis 2002;185:1818-21.
21. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-24.
22. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:332-40.
23. + T-cell changes independent of viral load. Blood 2004;104:942-7.
24. + cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-43.
25. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859-66.
26. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001;15:1749-56.
27. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71.
28. + cells after antiretroviral therapy. J Infect Dis 2008;198:1466-73.
29. Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20:2033-41.
30. Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002;186:1092-7.
31. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003;77:11212-9.
32. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005;191:348-57.
33. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-29.
34. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007;3:e46.